| Literature DB >> 35712466 |
Sung Jun Jo1, Kyeong Deok Kim1, So Hee Lim1, Jinseob Kim2, Seung Hyup Hyun3, Jae Berm Park1, Kyo Won Lee1.
Abstract
18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) was used to predict pathologic grades based on the maximum standardized uptake value (SUVmax) in soft tissue sarcoma and bone sarcoma. In retroperitoneal sarcoma (RPS), the effectiveness of PET was not well known. This study was designed to investigate the association of SUVmax with histopathologic grade and evaluate the usefulness of 18F-FDG PET/CT before operation. Patients at Samsung Medical Center undergoing primary surgery for retroperitoneal sarcoma with preoperative 18F-FDG PET/CT imaging between January 2001 and February 2020 were investigated. The relationship between SUVmax and histologic features was assessed. The association of SUVmax with overall survival (OS), local recurrence (LR), and distant metastasis (DM) were studied. Of the total 129 patients, the most common histologic subtypes were liposarcoma (LPS; 68.2%) and leiomyosarcoma (LMS; 15.5%). The median SUVmax was 4.5 (range, 1- 29). Moreover, SUVmax was correlated with tumor grade (p < 0.001, Spearman coefficient; 0.627) and mitosis (p < 0.001, Spearman coefficient; 0.564) and showed a higher value in LMS (12.04 ± 6.73) than in dedifferentiated liposarcoma (DDLPS; 6.32 ± 4.97, p = 0.0054). SUVmax was correlated with pathologic parameters (tumor grade and mitosis) in RPS and was higher in the LMS group than the DDLPS group. The optimal SUVmax threshold to distinguish high tumor grade was 4.8. Those with a SUVmax greater than the threshold showed poor prognosis regarding OS, LR, and DM (p < 0.001).Entities:
Keywords: DDLPS; LPS; PET; RPS; SUVmax
Year: 2022 PMID: 35712466 PMCID: PMC9197420 DOI: 10.3389/fonc.2022.868823
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Characteristics of patients.
| Variable | Value | |
|---|---|---|
| Age, years (mean) | 56.4 ± 12.2 | |
| Gender (%) | F | 67 (51.9) |
| M | 62 (48.1) | |
| BMI, kg/m2 (mean) | 23.5 ± 3.0 | |
| Underlying disease | ||
| DM | Yes | 11 |
| No | 118 | |
| HTN | Yes | 39 |
| No | 90 | |
| Chronic renal disease | Yes | 1 |
| No | 128 | |
| Histologic subtype (%) | Well-differentiated liposarcoma | 24 (18.6) |
| Dedifferentiated liposarcoma | 60 (46.5) | |
| Pleomorphic liposarcoma | 4 (3.1) | |
| Leiomyosarcoma | 20 (15.5) | |
| Malignant peripheral nerve sheath tumor | 4 (3.1) | |
| Perivascular epithelioid cell tumor | 1 (0.8) | |
| Other | 16 (12.4) | |
| FNCLCC grade (%) | 1 | 29 (22.5) |
| 2 | 36 (27.9) | |
| 3 | 64 (49.6) | |
| SUVmax (median [range]) | 4.5 [0.4, 29.0] | |
| Tumor size, mm (mean) | 166.4 ± 101.3 | |
| Multifocality (%) | Yes | 23 (17.8) |
| No | 106 (82.2) | |
| Necrosis (%) | Absent | 60 (46.5) |
| <50% | 60 (46.5) | |
| ≥50% | 9 (7.0) | |
| Mitosis (%) | <9/10 HPF | 95 (73.6) |
| 10-19/10 HPF | 24 (18.6) | |
| ≥20/10 HPF | 10 (7.8) | |
| Local recurrence (%) | Yes | 54 (41.9) |
| No | 75 (58.1) | |
| Distant metastasis (%) | Yes | 17 (13.2) |
| No | 112 (86.8) | |
| Follow up months after primary surgery, month (median[range]) | 37.8 [20.3, 71.9] |
Figure 1Comparison of median SUVmax with histologic subtypes.
Univariate and multivariate analyses of risk factors associated with overall survival.
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Male | 1.9 (0.98,3.66) | 0.057 | ||
| Age | 1.03 (1,1.06) | 0.033 | ||
| SUVmax | 1.11 (1.07,1.16) | < 0.001 | 1.09 (1.03,1.15) | 0.004 |
| Tumor size | 1 (1,1) | 0.815 | ||
| FNCLCC grade: ref. = 1 | ||||
| 2 | 0.93 (0.19,4.61) | 0.926 | 0.76 (0.15,4.01) | 0.749 |
| 3 | 6.06 (1.84,19.98) | 0.003 | 4.4 (0.83,23.45) | 0.083 |
| Histology: ref.=DDLPS | ||||
| WDLPS | 0.35 (0.1,1.21) | 0.097 | ||
| LMS | 0.89 (0.33,2.41) | 0.815 | ||
| MPNST | 1.48 (0.34,6.38) | 0.597 | ||
| Other | 1.18 (0.43,3.22) | 0.746 | ||
| Necrosis: ref.= Absent | ||||
| <50% | 3.26 (1.46,7.28) | 0.004 | 0.81 (0.24,2.74) | 0.74 |
| ≥50% | 6.49 (2.1,20.02) | 0.001 | 1.37 (0.33,5.73) | 0.666 |
| Mitosis: ref.= <9/10 HPF | ||||
| 10-19/10 HPF | 2.26 (1.06,4.81) | 0.035 | 0.7 (0.26,1.9) | 0.484 |
| ≥20/10 HPF | 4.63 (1.83,11.7) | 0.001 | 0.77 (0.21,2.81) | 0.69 |
Univariate and multivariate analyses of risk factors associated with local recurrence.
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Male | 1.14 (0.67,1.95) | 0.632 | ||
| Age | 1.01 (0.99,1.03) | 0.503 | ||
| SUVmax | 1.08 (1.04,1.12) | < 0.001 | 1.01 (0.94,1.08) | 0.855 |
| Tumor size | 1 (1,1) | 0.582 | ||
| FNCLCC grade: ref. = 1 | ||||
| 2 | 8.43 (1.9,37.39) | 0.005 | 7.27 (1.57,33.75) | 0.011 |
| 3 | 15.38 (3.69,64.04) | < 0.001 | 8.13 (1.54,42.92) | 0.014 |
| Histology: ref.=DDLPS | ||||
| WDLPS | 0.12 (0.03,0.51) | 0.004 | 0.19 (0.04,0.89) | 0.035 |
| LMS | 2.32 (1.22,4.43) | 0.011 | 1.93 (0.81,4.6) | 0.137 |
| MPNST | 3.22 (0.96,10.78) | 0.058 | 2.77 (0.75,10.19) | 0.126 |
| Other | 0.46 (0.14,1.52) | 0.206 | ||
| Necrosis: ref.= Absent | ||||
| <50% | 3.35 (1.77,6.33) | < 0.001 | 1.56 (0.76,3.21) | 0.23 |
| ≥50% | 13.9 (5,38.6) | < 0.001 | 6 (1.74,20.7) | 0.005 |
| Mitosis: ref.= <9/10 HPF | ||||
| 10-19/10 HPF | 3.38 (1.79,6.39) | < 0.001 | 1.37 (0.61,3.09) | 0.449 |
| ≥20/10 HPF | 2.99 (1.15,7.75) | 0.024 | 1.79 (0.4,7.91) | 0.444 |
Figure 2Receiver Operation Characteristic (ROC) curve for SUVmax.
Figure 3Kaplan-Meier survival graph compared to the SUVmax threshold of 4.8. (A) OS, LR, DM in RPS group, (B) OS, LR, DM in LPS group.